

TUESDAY, OCTOBER 6, 2020



This activity is provided by Med Learning Group.

This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM). Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Merck & Co, Inc.



Optimizing Treatment with Immune Checkpoint Inhibitors: The Collaborative Care of Patients with Triple Negative Breast Cancer

FACULTY

Sramila Aithal, MD Director and Lead, Breast Center of Advanced Oncology Medical Oncologist and Hematologist Cancer Treatment Centers of America Philadelphia, PA

PROGRAM OVERVIEW

This case-based live virtual activity will cover the treatment and management of patients with triple negative breast cancer.

TARGET AUDIENCE

This initiative is designed to meet the educational needs of U.S.-based nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians involved in the treatment of patients with triple negative breast cancer (TNBC).

LEARNING OBJECTIVES

Upon completion of the program, attendees should be able to:

- Explain the complementary mechanisms found with the combination of chemotherapy and immunotherapy agents in the treatment of TNBC
- Apply evidence-based data derived from clinical trials to optimize combination regimens for the treatment of patients with metastatic TNBC
- Describe patient-centered shared decision-making approaches intended to optimize oncology care in patients with TNBC
- Discuss the roles that oncology nurses can play in the management of patients with metastatic TNBC who are treated or eligible for treatment with immunotherapy

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live virtual activity for a maximum of 1.0 AMA Category 1 Credit[™]. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the management or treatment of patients with triple negative breast cancer. **CNE Credits:** 1 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education for RNs and APNs.



ONCC STATEMENT

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Sramila Aithal, MD is a Speakers' Bureau member for Pfizer, Novartis, Seattle Genetics and Puma. She was a principal investigator for pharmaceutical initiated clinical trials at CTCA.

CME Content Review

The content of this activity was independently peer-reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer-reviewed by a nurse reviewer. The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, General Manager of Med Learning Group has nothing to disclose.

Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.

Ana Maria Albino, Senior Program Manager of Med Learning Group has nothing to disclose.

Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group has nothing to disclose. Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose. Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.

ison, Accreditation and Outcomes coordinator for Med Learning Group, has nothing to t

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this live virtual activity. To receive CME/CNE credit participants must:

- 1. Read the CME/CNE information and faculty disclosures
- 2. Participate in the live virtual activity
- 3. Complete the posttest and online evaluation form

You will receive your certificate as a downloadable file.



DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at info@medlearninggroup.com Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating info@medlearninggroup.com



This activity is provided by Med Learning Group.



This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM).

This activity is implemented in partnership with the Houston ONS Chapter.

Supported by an educational grant from Merck & Co., Inc.

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.



Optimizing Treatment with Immune Checkpoint Inhibitors: The Collaborative Care of Patients with Triple Negative Breast Cancer

I. Primer in Triple-Negative Breast Cancer

- a. Molecular and immunogenic characteristics of TNBC
 - 1. What is triple-negative breast cancer?
 - 2. Tumor infiltrating lymphocytes and their role
 - 3. ASCO-CAP classification of TNBC
- b. Pathologic and clinical characteristics of TNBC
 - 1. The TNBC phenotype
 - 2. Antitumor immunity and the tumor microenvironment
- c. Standard of care treatments
 - 1. Unmet needs

II. Combination Therapy for Metastatic TNBC – Revealing the Additive or Synergistic Effects

- a. Understanding the complementary mechanisms found with the combination of chemotherapy and immunotherapy treatment
 - 1. How does chemotherapy augment tumor immunity?
 - 2. Preclinical and clinical data of chemotherapy/IO immunogenic effects
- b. Mechanisms of immune modulation by chemotherapy
- c. Combined anti-tumor effects of chemotherapy with checkpoint inhibition on TNBC

III. Rational Integration of Distinct Treatment Modalities for Metastatic TNBC

- a. Checkpoint inhibition and its efficacy, safety in TNBC
- b. Combination of IO and chemotherapy in the systemic treatment of TNBC
- c. Review of current IO and chemotherapy combination clinical trials results and their use in metastatic disease

IV. Case studies

V. Multidisciplinary Oncology Team – Optimizing Patient Care and Survivorship Through Shared Decision Making

- a. Benefits for patients and providers
- b. Use of SDM in oncology
- c. Barriers and facilitators to SDM
- d. Oncology nurses as integral members of the cancer care team

VI. Conclusions and Questions and Answers


Optimizing Treatment With Immune Checkpoint Inhibitors: The Collaborative Care of Patients With Triple-Negative Breast Cancer

Sramila Aithal, MD Chief of Medical Oncology Medical Director, Breast Oncology Cancer Treatment Centers of America Philadelphia, PA

Disclosures

- Sramila Aithal, MD is on the Speakers Bureau for Pfizer, Puma, Novartis and Seattle Genetics. Dr. Aithal has consulted for PSI-CRO.
- During the course of this lecture, Dr. Aithal may mention the use of medications for both FDA-approved and non-approved indications.

This activity is supported by an educational grant from Merck & Co., Inc.



Triple-Negative Breast Cancer: An Overview ≈ 10%-15% of all breast cancers • \approx 2 times more likely in African American women before 40 years of age as compared with Caucasian or Hispanic women • Up to 20% of TNBCs have germline BRCA mutation Shorter PFS and median survival in TNBC compared with other subtypes • TNBC has a high likelihood of visceral metastasis, including in the brain 5-year relative survival rates in TNBC (2010-2016) SEER Stage 5-Year Relative Survival Rate Localized 91.2% Regional 65.0% Distant 11.5% PFS = progression-free survival; SEER = Surveillance, Epidemiology, and End Results.


Foulkes WD, et al. N Engl J Med. 2010;363:1938-1948. Centers for Disease Control and Prevention 2019 (https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/types-of-breast-cancer/triple-negative.html). Accessed August 27, 2020. National Institutes of Health Cancer Stat Facts (https://seer.cancer.gov/statfacts/html/breast-subtypes.html). Accessed August 28, 2020. Khosravi-Shahi P, et al. Asia Pac J Clin Oncol. 2018;14:32-39.

ASCO/CAP Classification of TNBC

- Hormone receptor status
 - Receptor positive: > 1% of tumor cells are positive for ER or PR
 - Receptor negative: ER and/or PR IHC expression of 0
- HER2 amplification status
 - HER2+: IHC protein expression of 3+
 - HER2-: IHC expression of 0 or 1+
 - If IHC result is 2+ (equivocal), perform dual-probe ISH
- TNBC: ER-, PR-, and HER2-


20	2018 ASCO/CAP dual-probe HER2 ISH interpretation					
Group	<i>HER2</i> /CEP17 Ratio	HER2 Signals/ Cell	Interpretation	Further Workup and Interpretation		
1	≥2	≥ 4	ISH positive			
2	≥2	< 4	Further workup	Correlate with IHC; if 2+, count additional ISH cells HER2 NEGATIVE unless		
				IHC 3+		
3	< 2	≥ 6	Further workup	Correlate with IHC; if 2+, count additional ISH cells HER2 POSITIVE unless IHC 0 or 1+		
4	< 2	≥ 4 and < 6	Further workup	Correlate with IHC; if 2+, count additional ISH cells HER2 NEGATIVE unless IHC 3+		
5	< 2	< 4	ISH negative			

ER = estrogen receptor; IHC = immunohistochemistry; ISH = in situ hybridization; PR = progesterone receptor. Hammond MEH, et al. J Clin Oncol. 2010;28:2784-2795. Wolff AC, et al. J Clin Oncol. 2018;36:2105-2122. Wolff AC, et al. Arch Pathol Lab Med. 2018;142:1364-1382. Foulkes WD, et al. N Engl J Med. 2010;363:1938-1948.




Tumor-Infiltrating Lymphocytes (TILs)

- Approximately 11% of breast cancers demonstrate LPBC
- TILs are most commonly found in highly proliferative cancers such as TNBC and HER2+ tumors
- TNBCs have the highest incidence of LPBC (range: 4%-37%)




- GeparDuo and GeparTrio trials
 - Phase 3 trials of docetaxel, doxorubicin, and cyclophosphamide combination regimens
- LPBC was defined as patients with > 60% intratumoral or stromal lymphocytes
- The percentage of intratumoral lymphocytes was a significant independent predictor of pCR, with an OR of 1.38 (95% CI: 1.08, 1.78; P= .012) for every 10% increase in lymphocyte infiltrate

LPBC = lymphocyte-predominant breast cancer; OR = odds ratio; pCR = pathological complete response. Stanton SE, et al. JAMA Oncol. 2016;2:1354-1360. Loi S, et al. J Clin Oncol. 2013;31:860-867. Denkert C, et al. J Clin Oncol. 2010;28:105-113. Images courtesy of Carsten Denkert.



Harvey RD. Clin Pharmacol Ther. 2014;96:214-23. Dyck L, Mills KHG. Eur J Immunol. 2017;47:765-779.






Chemotherapy Can Sensitize Tumors to Checkpoint Blockade


Although chemotherapy can be immune suppressive, the *right* agents in the *right* doses at the *right* time can induce T-cell infiltration into tumors:

- Cyclophosphamide
- Platinums
- Anthracyclines
- Taxanes





TLR4 = toll-like receptor 4. Pfirschke C, et al. *Immunity*. 2016;44:343-354.

11



*ClinicalTrials.gov: NCT02425891. *Locally evaluated per American Society of Clinical Oncology (ASCO)–College of American Pathologists guidelines. *Centrally evaluated per VENTANA SP142 IHC assay (double blinded for PD-L1 status). *Radiologic endpoints were investigator assessed (per RECIST v1.1). DOR = duration of response; ECOG = Eastern Cooperative Oncology Group; IC = immun cell; ITT = intention-to-treat; IV = intravenous; ORR = objective response rate; OS = overall survival; PS = performance status. Schmid P, et al. 8. *Incl J* Med. 2018;379:2108-2121. SchWO 2018. Presentation LBA1 PR.





IMpassion130: Adverse Events						
		+ <i>nab</i> -Paclitaxel 452)	Placebo + <i>nab</i> -Paclitaxel (n = 438)			
	Any Grade	Grade 3 or 4	Any Grade	Grade 3 or 4		
Event		Number of patie	ents with event (%)			
Alopecia	255 (56.4)	3 (0.7)	252 (57.5)	1 (0.2)		
Nausea	208 (46.0)	5 (1.1)	167 (38.1)	8 (1.8)		
Cough	112 (24.8)	0	83 (18.9)	0		
Peripheral neuropathy	98 (21.7)	25 (5.5)	97 (22.1)	12 (2.7)		
Neutropenia	94 (20.8)	37 (8.2)	67 (15.3)	36 (8.2)		
Pyrexia	85 (18.8)	3 (0.7)	47 (10.7)	0		
Hypothyroidism	62 (13.7)	0	15 (3.4)	0		

Shown are the single most frequent AEs of any grade, AEs of any grade for which the rates differed by \geq 5 percentage points between groups, and AEs of grade 3 or 4 for which the rates differed by \geq 2 percentage points between groups


	Pembrolizumab	WOIN	Juiera				
 Pembrolizumal mTNBC¹⁻⁴ 	o monotherapy showed	durable	antitumo	or activity and mar	nageable safet	y in patie	nts with
Improved clinic	cal responses observed	in patien	ts with h	igher PD-L1 expres	ssion ⁴		
Responses to p	embrolizumab monoth	erapy we	ere more	durable than thos	e to chemothe	erapy ⁴	
Study	Population	N	ORR	Median DOR (range), mo	Median PFS (95% CI), mo	6-Month PFS	12-Month OS
Study KEYNOTE-012 ¹	Population Heavily pretreated PD-L1–positive*	N 27	ORR 18.5%				
	Heavily pretreated			(range), mo	(95% CI), mo	PFS	OS
KEYNOTE-012 ¹	Heavily pretreated PD-L1–positive* Previously treated	27	18.5%	(range), mo NR (3.4 to 10.8+)	(95% Cl), mo	PFS 24.4%	OS 43.1%


*Expression in stroma or ≥ 1% of TCs by IHC and the 22C3 antihuman PD-1 antibody (Merck & Co., Kenilworth, NJ). ⁺Assessed at a central laboratory using the PD-L1 IHC 22C3 pharmDx assay defined as the CPS, the number of PD-L1–positive cells (TCs, lymphocytes, macrophages) divided by total number of TCs x 100; PD-L1–positive = CPS ≥ 1. CPS = combined positive score; NR = not reached. 1. Nanda R, et al. *J Clin Oncol.* 2016;34:2460-2467. 2. Adams S, et al. *Ann Oncol.* 2019;30:397-404. 3. Adams S, et al. *Ann Oncol.* 2019;30:405-411. 4. Cortes J, et al. *Ann Oncol.* 2019;30(suppl 5):v859-v860. Cortes J, et al. ASCO 2020: presentation 1000.

AE = adverse event. Schmid P, et al. N Engl J Med. 2018;379:2108-2121.


Pembrolizumab Plus Chemotherapy Ocenenotherapy is a rational combination partner for anti–PD-1 therapy¹ Disrupts tumor architecture and may overcome immune exclusion Results in antigen shedding Induces rapid disease control Pembrolizumab + standard neoadjuvant chemotherapy Demonstrated a pCR rate of 60% across all cohorts in KEYNOTE-173² More than doubled estimated pCR rates for HR-positive/*ERBB2*-negative and TNBC in I-SPV2³ Statistically significant increase in pCR of 13.6 percentage points (*P* = .001) vs chemotherapy alone in <u>KYNOTE-522⁴</u> Manageable toxicity with no unexpected safety signals²4 Pembrolizumab + chemotherapy was granted FDA breakthrough therapy designation for neoadjuvant treatment of patients with high-risk, early stage TNBC

FDA = US Food and Drug Administration; pCR = pathologic complete response. 1. Economopoulou P, et al. Ann Oncol. 2016;27:1675-1685. 2. Schmid P, et al. Ann Oncol. 2020;31:569-581. 3. Nanda R, et al. JAMA Oncol. 2020;6:1-9. 4. Schmid P, et al. N Engl J Med. 2020;382:810-821.








19




Cortes J, et al. J Clin Oncol. 2020;38(15 suppl): abstract 1000. Cortes J, et al. ASCO 2020. Abstract 1000.












Where to Draw the Line for Neoadjuvant Immunotherapy?




Are the current trial data supportive of using immunotherapy in the neoadjuvant setting?


- Is improvement in pCR alone adequate?
- What about the increased rate of immunemediated AEs?













Pembrolizumab Graduated in All HER2- Signatures: Both HR+/HER2- and Triple Negative						
Signature	Estimated (95%	pCR Rate 6 PI)	Probability Pembrolizumab	Predictive Probability of		
Signature	Pembrolizumab	Control	Is Superior to Control	Success in Phase 3		
All HER2-	0.46 (0.34-0.58)	0.16 (0.06-0.27)	> 99%	99%		
TNBC	0.60 (0.43-0.78)	0.20 (0.06-0.33)	> 99%	> 99%		
HR+/HER2-	0.34 (0.19-0.48)	0.13 (0.03-0.24)	> 99%	88%		


• The Bayesian model estimated pCR rates appropriately adjust to characteristics of the I-SPY2 population


• The raw pCR rates (not shown) are higher than the model estimate of 0.604 in TNBC


PI = probability interval. Nanda R, et al. ASCO 2017. Abstract 506.













		pCR by Key Patie	· · ·	
pCR, % (n/N)		Pembrolizumab + Chemotherapy (n = 401)	Placebo + Chemotherapy (n = 201)	∆ (95% CI)
Disease stage	 IIA IIB IIIA IIIB 	73.1 (133/182) 56.2 (68/121) 66.7 (40/60) 48.6 (18/37)	62.1 (54/87) 48.4 (30/62) 42.1 (16/38) 23.1 (3/13)	11.0 (-0.7, 23.2) 7.8 (-7.4, 22.8) 24.6 (4.3, 43.1) 25.6 (-6.1, 48.9)
Lymph node involvement	NegativePositive	64.9 (124/191) 64.8 (136/210)	58.6 (58/99) 44.1 (45/102)	6.3 (-5.3, 18.2) 20.6 (8.9, 39.1)
PD-L1 expression	 CPS < 1 CPS ≥ 1 CPS ≥ 10 CPS ≥ 20 	45.3 (29/64) 68.9 (230/334) 77.9 (162/208) 81.7 (103/126)	30.3 (10.33) 54.9 (90/164) 59.8 (55/92) 62.5 (40/64)	18.3 (-3.3, 36.8) 14.2 (5.3, 23.1) 17.5 (6.2, 29.1) 18.5 (5.0, 32.7)
Chemotherapy exposure*	 Full exposure < Full exposure 	69.7 (314/307) 51.1 (46/90)	55.3 (88/159) 35.7 (15/42)	14.4 (5.1, 3.6) 15.4 (-3.0, 32.1)


*Full exposure comprised paclitaxel weekly 10-12 doses, carboplatin weekly 10-12 doses or Q3W 4 doses, doxorubicin or epirubicin Q3W 4 doses, and cyclophosphamide Q3W 4 doses, regardless of exposure to pembrolizumab.


Schmid P, et al. SABCS 2019. Abstract GS3-03.












NeoTRIPaPDL1: Summary

- The addition of atezolizumab to neoadjuvant chemotherapy resulted in slightly higher rates of pCR when compared with neoadjuvant chemotherapy alone in the ITT population (43.5% vs 40.8%); however, the increase was not statistically significant
- Among patients whose tumors tested positive for PD-L1, 51.9% of patients in the atezolizumab + chemotherapy arm had pCR compared with 48.0% in the chemotherapyonly arm
- PD-L1 does not predict who benefits from adding checkpoint inhibitor


Summary of Key Immuno-oncology Trials in TNBC						
Setting	Study Name	Study Treatment	Outcome: ITT			
		Paclitaxel + carboplatin AC/EC	Pembrolizumab/	\checkmark		
Neoadjuvant	KEYNOTE-522 ¹	Pembrolizumab/placebo (24 weeks)	placebo (29 weeks)	pCR 64.8% with pembrolizumab vs 51.2%		
		Nab-paclitaxel + carboplatin AC/EC/FEC		pCR 43.5% with		
	NeoTRIPaPDL1 ²	Atezolizumab/placebo (24 weeks) (12 weeks)		atezolizumab vs 40.8%		
1L	IMpassion 130 ^{3,†}	<i>Nab</i> -paclitaxel ± atezoliz	PFS: HR = 0.80, <i>P</i> = .0021			
metastatic	KEYNOTE-355 ⁴	Pembrolizumab vs <i>nab</i> -pa paclitaxel/carboplatin + gen	PFS: HR = 0.82 (0.69-0.97)			
2L-3L metastatic	KEYNOTE-119⁵	Pembrolizumab vs capeci eribulin/gemcitabine/vino	No significant improvement in OS with pembrolizumab			
		Surgery				

AC = doxorubicin and cyclophosphamide; EC = epirubicin and cyclophosphamide; FEC = fluorouracil, epirubicin, and cyclophosphamide. 1. Schmid P, et al. ESMO 2019. Abstract LBA8_PR. 2. Gianni L, et al. SABCS 2019. Abstract GS3-04. 3. Schmid P, et al. N Engl J Med. 2018;379:2108-2121. 4. Cortes J, et al. ASCO 2020. Abstract 1000. 5. Cortes J, et al. ESMO 2019. Abstract LBA21. Hamilton E. ASCO 2020. Abstract 1000. 5. Cortes J, et al. ESMO 2019. Abstract LBA21. Hamilton E. ASCO 2020.











Immune-Related Adverse Events: Grading and Management Principles


Severity— CTCAE Grade	Ambulatory vs Inpatient Care	Corticosteroids	Other Immunosuppressive Drugs	Immunotherapy
1 Mild	Ambulatory	Not recommended	Not recommended	Continue with close monitoring (exception neurologic/some hematologic and cardiac toxicities)
2 Moderate	Ambulatory	Topical steroids or systemic steroids oral (low-dose) 0.5-1 mg/kg/d	Not recommended	Suspend temporarily* until symptoms and/or laboratory values revert to grade 1 levels or lower
3 Severe	Hospitalization	Systemic steroids (high-dose) Oral <i>or</i> IV 1-2 mg/kg/d x 3 days, then reduce to 1 mg/kg/d; long taper (≥1 month)	To be considered for unresolved symptoms after 3-5 days of steroids Organ specialist referral advised	Suspend and discuss resumption based on risk/benefit ratio with patient
4 Very severe	Hospitalization; consider intensive care unit	Systemic steroids (high dose) IV methylprednisolone 1-2 mg/kg/d x 3 days, then reduce to 1 mg/kg/d; long taper (≥1 month)	To be considered for unresolved symptoms after 3-5 days of steroids Organ specialist referral advised	Discontinue permanently


Some dysimmune toxicities may follow a specific management; this must be discussed with the organ specialist. *In the case of skin or endocrine disorders, immunotherapy can be maintained. CTCAE = Common Terminology Criteria for Adverse Events.

Champiat S, et al. Ann Oncol. 2016;27:559-574. Brahmer JR, et al. J Clin Oncol. 2018;36:1714-1768.






















Case Study 1: Question 1

Sandra B is a 54-year-old postmenopausal woman who was diagnosed with early stage invasive ductal carcinoma of the right breast 2 years ago with a 3-cm lesion and no nodal involvement, triple-negative, high-grade histology, BRCA1- and BRCA2-negative. She declined neoadjuvant chemotherapy, underwent bilateral mastectomy, received adjuvant chemotherapy and no radiation, and had minimal side effects. She remained without disease free for 23 months and presented with right hip pain, weight loss, and fatigue. Imaging studies showed a 2-cm right acetabular lesion, iliac and sacral metastasis, besides lung nodules and liver lesion. Brain MRI was negative. Biopsy of the lung lesion confirmed mTNBC, and PD-L1 was positive with SP-142 antibody.

What is the most appropriate treatment option for this patient?

- A. Capecitabine
- B. Carboplatin and gemcitabine
- C. Atezolizumab and nab-paclitaxel
- D. Paclitaxel

MRI = magnetic resonance imaging.

	Case Study 1: Question 2
vomitin hypona	ient receives atezolizumab and <i>nab</i> -paclitaxel. After 3 months of therapy, she presents with anorexia, g, abdominal pain, weakness, lethargy, and intermittent fever. Laboratory findings showed tremia, low blood sugars, low morning cortisol levels, and elevated ACTH. She is diagnosed with adrenal insufficiency as an adverse effect of immunotherapy.
You mai	nage this patient with all of the following <i>except</i> :
A. Redu	uce the dose and continue with immunotherapy
B. Requ	uest an endocrine consultation
C. Add	prednisone or hydrocortisone and titrate the doses based on symptoms
D. Obta	in an MRI of the brain

Case Study 2

Katie B is a 60-year-old postmenopausal woman who is diagnosed with stage III TNBC and is on pembrolizumab + chemotherapy on a clinical trial. She has no past medical history. After 4 cycles of therapy, she presents with worsening shortness of breath on exertion and a dry, nonproductive cough. She denies any fevers or chills or recent sick contacts. She has a drop in oxygen level to 94% at walking; however at rest, she is breathing comfortably and fully conversant.


What is the most appropriate next step in management?

A. Hold chemoimmunotherapy and emergently initiate corticosteroids for immune-related pneumonitis

B. Hold chemoimmunotherapy, obtain a chest CT, and consider additional workup for immune-related pneumonitis

C. Continue chemoimmunotherapy treatment and refer the patient to a pulmonary specialist for further workup and management

D. Hold chemoimmunotherapy and begin oral antibiotics for bacterial pneumonia



Role of Oncology Nursing in IO Management

- Nurses should be aware of the mechanisms of immunotherapy and safe administration, which is different from that of cytotoxic agents
- Immunotherapy is often given in combination with chemotherapy or during radiation; dose reduction is not necessary
- Onset of immune-related AEs occurs later than the infusion time; nurses should be well versed and assess and monitor for possible immune-related AEs
- Nurses should educate patients about side effects of IO and encourage them to be engaged in informing them of the side effects
- Safety standards set by ASCO and Oncology Nursing Society guidelines should be the basis for policies and procedures for IO administration



